Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040985 | 0.88 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| SCHEMBL2295833 | 0.87 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| SCHEMBL14040903 | 0.85 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| Hydrochloric Acid SCHEMBL7110024 | 0.85 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| SCHEMBL7577192 | 0.84 | ALDH1A1 (0.97) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| SCHEMBL2553452 | 0.82 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2GAAPKMCYP2C9 | |
| SCHEMBL1514453 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GAAKDM4ECYP1A2 | |
| SCHEMBL14502540 | 0.78 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| SCHEMBL3417681 | 0.78 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2GAAPKMKDM4E | |
| SCHEMBL7110016 | 0.78 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2GAAPKMCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711027-B2 | DNA polymerase beta inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-07-04 | — | — | US | disclosed |
| US-8093272-B2 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093272-B2 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| WO-2008024759-A2 | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE PY+3 BINDING SITE OF TYROSENE KINASE P56 LCK SH2 DOMAIN | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070196395-A1 | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | UNIVERSITY OF MARYLAND, BALTIMORE | 2007-08-23 | — | — | US | disclosed |
| US-20070196395-A1 | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | UNIVERSITY OF MARYLAND, BALTIMORE | 2007-08-23 | — | — | US | disclosed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070099970-A1 | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain | UNIVERSITY OF MARYLAND, BALTIMORE | 2007-05-03 | — | — | US | disclosed |
| US-20070099970-A1 | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain | UNIVERSITY OF MARYLAND, BALTIMORE | 2007-05-03 | — | — | US | disclosed |
| EP-1054868-B1 | SUBSTITUTED PYRIDINO ARYLPIPERAZINES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ORTHO MCNEIL PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1121390-C | Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6218396-B1 | SELECTIVELY INHIBITS BINDING TO AN ADRENERGIC RECEPTOR | ORTH-MCNEIL PHARMACEUTICAL, INC. | 2001-04-17 | — | — | US | disclosed |
| CN-1291188-A | Novel substituted pyridylarylpiperazine compounds for the treatment of benign prostatic hyperplasia | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2001-04-11 | — | — | CN | disclosed |
| EP-1054868-A1 | NOVEL SUBSTITUTED PYRIDINO ARYLPIPERAZINES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999042448-A1 | NOVEL SUBSTITUTED PYRIDINO ARYLPIPERAZINES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099970-A1 | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain | LCK, PTPN6, PTPN22 | ALDH1A1 4878/4885SMN1; SMN2 3437/4885GAA 4124/4885 |
| US-10711027-B2 | DNA polymerase beta inhibitors | POLB, POLH, POLN | ALDH1A1 908/4885SMN1; SMN2 3777/4885GAA 158/4885 |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | DDC, DPYD, PKD1 | ALDH1A1 119/4885SMN1; SMN2 1685/4885GAA 24/4885 |
| US-20190202853-A1 | DNA POLYMERASE BETA INHIBITORS | POLB, POLH, POLN | ALDH1A1 908/4885SMN1; SMN2 3777/4885GAA 158/4885 |
| US-20070196395-A1 | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | LCK, PTPN6, PTPN22 | ALDH1A1 4878/4885SMN1; SMN2 3437/4885GAA 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.